Cancers from individuals heterozygous for CHEK2 gPVs presented with mutational signatures SBS1 and/or SBS5 in 12/28 (43%; P = 1) and 12/28 (43%; P < .05) cancers, respectively (Figure 1, D). Here, CHEK2 is linked to cancer.